decisionhealth Newsletters, Part B News - 2004 Issue 7 (July)
Epoetin proposal would change payment rules for ESRD patients
Subscribe or sign in to view the full article.
Article Overview
This article covers a CMS draft coverage policy related to payment for erythropoietin products used in end stage renal disease care. It is relevant to nephrology, dialysis billing, and Medicare reimbursement professionals who need to understand the broad contours of the proposed changes, the claims information CMS expects, and the public comment process.
Why This Topic Matters
The proposed policy could affect how ESRD-related anemia treatment is paid and reviewed under Medicare, making it important for providers and billing staff who report these services.
What You Will Learn
- The general purpose of the proposed CMS policy
- How the article frames payment and medical review changes for ESRD-related anemia treatment
- What kinds of claim information CMS expects to be reported
- The public comment timeline and agency contact context
Who Should Read This
- Nephrologists
- Dialysis facility billing staff
- Medical coders
- Medicare reimbursement specialists
- Revenue cycle staff
- Healthcare compliance professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com